Page last updated: 2024-08-23

etoposide and Multiple Sclerosis, Relapsing-Remitting

etoposide has been researched along with Multiple Sclerosis, Relapsing-Remitting in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Barnett, MH; Barnett, Y; Ford, CD; Hendrawan, K; Khoo, ML; Kyle, KA; Ma, DDF; Ma, KC; Massey, JC; Milliken, ST; Moore, JJ; Sutton, IJ; Zaunders, JJ; Zivadinov, R	1

Trials

1 trial(s) available for etoposide and Multiple Sclerosis, Relapsing-Remitting

Article	Year
Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis. Journal of neurology, neurosurgery, and psychiatry, 2019, Volume: 90, Issue:5 Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Progression-Free Survival; Prospective Studies; Transplantation, Autologous; Treatment Outcome; Young Adult	2019

Article

Year

Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis.

Journal of neurology, neurosurgery, and psychiatry, 2019, Volume: 90, Issue:5

Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Progression-Free Survival; Prospective Studies; Transplantation, Autologous; Treatment Outcome; Young Adult

2019